Vaccines
Updated Vaccines for Fall 2023
Moderna and Pfizer-BioNTech
- mRNA-based vaccine made to target omicron variant XBB.1.5
- Also expected to be effective against more recent virus strains, including EG.5 and BA.2.86
- Also expected to be effective against more recent virus strains, including EG.5 and BA.2.86
- Most widely available vaccine in the US currently (as of 10/6)
- authorized in the US for individuals 5yrs and up
- Protein-based vaccine made to target omicron variant XBB.1.5
- Also expected to be effective against more recent virus strains
- "The Novavax vaccine [was built with] a much older technology for vaccine development where, instead of injecting the genetic recipe, we actually inject the protein. It [uses] a combination of spike proteins that form what are called nanoparticles, which group together. The Novavax vaccine also has an adjuvant, an immune stimulant to get a better immune response."Article from Johns Hopkins School of Public Health. July 2022.
- Authorized in the US for individuals 12yrs and up